1. Transcriptome changes during peanut oral immunotherapy and omalizumab treatment
- Author
-
Jon R Konradsen, Simon Kebede Merid, Anna Nopp, Fredrik Fagerström-Billai, Korneliusz Golebski, Josef Brandström, David Brodin, Anke H. Maitland-van der Zee, Uroš Potočnik, Caroline Nilsson, Cornelis M. van Drunen, Erik Melén, Susanne J. H. Vijverberg, Marieke van der Heiden, Michael Kabesch, Sophia Björkander, Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, Paediatric Pulmonology, and APH - Personalized Medicine
- Subjects
Allergy ,Arachis ,medicine.medical_treatment ,Immunology ,Peanut allergy ,Administration, Oral ,Omalizumab ,medicine.disease_cause ,Allergen ,Food allergy ,medicine ,Immunology and Allergy ,Humans ,Peanut Hypersensitivity ,Desensitization (medicine) ,business.industry ,Immunotherapy ,Allergens ,medicine.disease ,Desensitization, Immunologic ,Pediatrics, Perinatology and Child Health ,business ,Transcriptome ,Anaphylaxis ,medicine.drug - Abstract
Peanut allergy is a common food allergy and the main cause of anaphylaxis among children1 . In recent years, oral immunotherapy has emerged as a promising treatment for children with different IgE-mediated food allergies, although safety issues must be considered2 . The main aim of immunotherapy is to induce tolerance or desensitization to an allergen which otherwise causes an allergic reaction. For oral immunotherapy this means ingesting the allergen in a controlled manner with gradually increasing dosages.
- Published
- 2022